背景:血液学参数是疾病严重程度和慢性病发病机制的关键因素。我们旨在评估不同时间间隔COVID-19不同严重程度阶段的血液学因素。
方法:从470名患者(235名男性和235名女性)中收集血清样本,经证实的RT-qPCRCOVID-19测试显示中度,严重,和根据世卫组织标准的危重症状。每隔三次收集样本,包括感染的第一天,第二:一个月后,第三:发病后三个月。WBC总数,中性粒细胞,淋巴细胞,单核细胞,嗜酸性粒细胞,红细胞计数,Hb,HCT,MCV,MCH,MCHC,hsCRP水平,G6PD缺乏症,并确定了所有患者的血红蛋白病。
结果:总WBC,中性粒细胞,淋巴细胞,血小板,红细胞计数,Hb,HCT,MCV,MCH,和hsCRP水平随着疾病严重程度的不同而显著改变(p<0.0001>60)。此外,除单核细胞和嗜酸性粒细胞外,WBC和RBC参数在不同时间间隔之间存在显着差异(p&#60;0.0001)。在所有时间间隔,基于性别,血液学和hsCRP水平有显著变化.此外,观察到疾病严重程度之间存在显着相关性,年龄,和BMI(p&#60;0.0001)。
结论:根据疾病严重程度,血液学参数和炎症参数水平存在显著差异,时间间隔,和性别揭示了评估这些因素在传染病管理中的重要性,如COVID-19,患者在疾病期间和疾病后时间。。
BACKGROUND: Hematological parameters are crucial factors in disease severity and chronic condition pathogenesis. We aimed to evaluate the hematological factors in different severity stages of COVID-19 at different time intervals.
METHODS: Serum samples were collected from 470 patients (235 men and 235 women) with a confirmed RT-qPCR COVID-19 test exhibiting moderate, severe, and critical symptoms based on WHO criteria. Samples were collected at three-time intervals, including the first: the 1st days of infection, 2nd: the one month after, and 3rd: the three months after disease onset. Total WBC, neutrophil, lymphocyte, monocyte, eosinophil,
RBC counting, Hb, HCT, MCV, MCH, MCHC, hsCRP levels, G6PD deficiency, and hemoglobinopathies were determined in all patients.
RESULTS: Total WBC, neutrophil, lymphocyte, platelet,
RBC counting, Hb, HCT, MCV, MCH, and hsCRP levels were significantly changed with different disease severity (p<0.0001). Also, there were significant differences between different time intervals for WBC and
RBC parameters (p<0.0001) except for monocytes and eosinophils. At all time intervals, there are significant changes in levels of hematological and hsCRP based on gender. Moreover, a significant correlation was observed between disease severity, age, and BMI (p<0.0001).
CONCLUSIONS: Significant differences in hematological parameter and inflammatory parameter levels based on disease severity, time intervals, and gender revealed the importance of evaluating these factors in the management of infectious diseases, such as COVID-19, in patients during and post-disease times..